| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Net sales | $ | 102,750 | $ | 86,231 | $ | 652,862 | $ | 560,968 | |||||||||||||||
| Cost of goods sold | 56,358 | 44,336 | 277,712 | 243,882 | |||||||||||||||||||
| Gross profit | 46,392 | 41,895 | 375,150 | 317,086 | |||||||||||||||||||
| Operating expenses (income): | |||||||||||||||||||||||
| Selling, general and administrative expense | 21,832 | 21,013 | 77,575 | 66,901 | |||||||||||||||||||
| Amortization expense | 15,794 | 13,741 | 59,696 | 55,032 | |||||||||||||||||||
| Founders advisory fees - related party | 171,209 | (54,789) | 435,163 | 198,308 | |||||||||||||||||||
| Other operating expense | 2,721 | 612 | 3,646 | 612 | |||||||||||||||||||
| Total operating expenses (income) | 211,556 | (19,423) | 576,080 | 320,853 | |||||||||||||||||||
| Operating (loss) income | (165,164) | 61,318 | (200,930) | (3,767) | |||||||||||||||||||
| Other expense (income): | |||||||||||||||||||||||
| Interest expense, net | 9,691 | 9,169 | 39,135 | 40,461 | |||||||||||||||||||
| Foreign currency loss (gain) | 211 | 2,280 | (3,038) | 2,443 | |||||||||||||||||||
| Other (income) expense, net | (638) | (60) | (780) | 192 | |||||||||||||||||||
| Total other expense, net | 9,264 | 11,389 | 35,317 | 43,096 | |||||||||||||||||||
| (Loss) income before income taxes | (174,428) | 49,929 | (236,247) | (46,863) | |||||||||||||||||||
| Income tax benefit | 34,197 | 94,241 | 29,881 | 40,958 | |||||||||||||||||||
| Net (loss) income | (140,231) | 144,170 | (206,366) | (5,905) | |||||||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Foreign currency translation adjustments | 3,184 | (23,627) | 32,862 | (19,522) | |||||||||||||||||||
| Total comprehensive (loss) income | $ | (137,047) | $ | 120,543 | $ | (173,504) | $ | (25,427) | |||||||||||||||
| (Loss) earnings per share: | |||||||||||||||||||||||
| Basic | $ | (0.94) | $ | 0.98 | $ | (1.37) | $ | (0.04) | |||||||||||||||
| Diluted | $ | (0.94) | $ | 0.90 | $ | (1.37) | $ | (0.04) | |||||||||||||||
| Weighted average number of shares outstanding: | |||||||||||||||||||||||
| Basic | 148,808,784 | 147,058,719 | 150,370,533 | 145,713,439 | |||||||||||||||||||
| Diluted | 148,808,784 | 160,931,755 | 150,370,533 | 145,713,439 | |||||||||||||||||||
| December 31, 2025 | December 31, 2024 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 325,927 | $ | 198,456 | |||||||
| Accounts receivable, net | 64,363 | 56,048 | |||||||||
| Inventories | 139,634 | 116,347 | |||||||||
| Prepaid expenses and other current assets | 34,049 | 23,173 | |||||||||
| Total current assets | 563,973 | 394,024 | |||||||||
| Property, plant and equipment, net | 85,138 | 64,777 | |||||||||
| Operating lease right-of-use assets | 30,152 | 17,298 | |||||||||
| Finance lease right-of-use assets | 5,713 | 6,173 | |||||||||
| Goodwill | 1,065,211 | 1,034,543 | |||||||||
| Customer lists, net | 628,189 | 637,745 | |||||||||
| Technology and patents, net | 184,804 | 173,307 | |||||||||
| Tradenames, net | 86,330 | 87,365 | |||||||||
| Other assets, net | 3,497 | 1,162 | |||||||||
| Total assets | $ | 2,653,007 | $ | 2,416,394 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 30,301 | $ | 23,519 | |||||||
| Accrued expenses and other current liabilities | 47,212 | 30,450 | |||||||||
| Founders advisory fees payable - related party | 95,726 | 6,677 | |||||||||
| Deferred revenue | 1,879 | 1,842 | |||||||||
| Total current liabilities | 175,118 | 62,488 | |||||||||
| Long-term debt, net | 669,122 | 667,774 | |||||||||
| Operating lease liabilities, net of current portion | 27,860 | 15,540 | |||||||||
| Finance lease liabilities, net of current portion | 5,694 | 6,013 | |||||||||
| Deferred income taxes | 80,410 | 152,203 | |||||||||
| Founders advisory fees payable - related party | 440,697 | 240,083 | |||||||||
| Preferred stock | 115,904 | 109,966 | |||||||||
| Preferred stock - related party | 1,293 | 2,831 | |||||||||
| Other non-current liabilities | 3,590 | 2,226 | |||||||||
| Total liabilities | 1,519,688 | 1,259,124 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
Common stock, $0.0001 par value per share, 4,000,000,000 shares authorized; 174,818,216 and 169,426,114 shares issued; 149,440,060 and 147,822,633 shares outstanding at December 31, 2025 and 2024, respectively | 17 | 17 | |||||||||
Treasury stock, at cost; 25,378,156 and 21,603,481 shares at December 31, 2025 and 2024, respectively | (168,197) | (127,827) | |||||||||
| Additional paid-in capital | 2,100,958 | 1,911,035 | |||||||||
| Accumulated other comprehensive loss | (6,370) | (39,232) | |||||||||
| Accumulated deficit | (793,089) | (586,723) | |||||||||
| Total stockholders’ equity | 1,133,319 | 1,157,270 | |||||||||
| Total liabilities and stockholders’ equity | $ | 2,653,007 | $ | 2,416,394 | |||||||
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (206,366) | $ | (5,905) | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Founders advisory fees - related party (change in fair value) | 435,163 | 198,308 | |||||||||
| Depreciation and amortization expense | 74,032 | 65,718 | |||||||||
| Interest and payment-in-kind on preferred stock | 7,332 | 7,057 | |||||||||
| Stock-based compensation | 16,647 | 12,849 | |||||||||
| Non-cash lease expense | 6,861 | 5,070 | |||||||||
| Deferred income taxes | (74,144) | (99,557) | |||||||||
| Amortization of deferred financing costs | 1,907 | 1,730 | |||||||||
| Foreign currency (gain) loss | (3,038) | 2,443 | |||||||||
| Loss on disposal of assets | 149 | 66 | |||||||||
| Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
| Accounts receivable | (6,954) | (13,293) | |||||||||
| Inventories | (5,980) | 29,872 | |||||||||
| Prepaid expenses and other current assets | 971 | (843) | |||||||||
| Accounts payable | 6,228 | (754) | |||||||||
| Deferred revenue | 37 | 1,842 | |||||||||
| Income taxes payable, net | (5,685) | (13,299) | |||||||||
| Accrued expenses and other current liabilities | 4,159 | 4,306 | |||||||||
| Founders advisory fees - related party (cash settled) | (6,677) | (2,702) | |||||||||
| Operating lease liabilities | (4,867) | (3,278) | |||||||||
| Finance lease liabilities | (489) | (501) | |||||||||
| Other, net | (1,137) | (741) | |||||||||
| Net cash provided by operating activities | 238,149 | 188,388 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchase of property and equipment | (29,591) | (15,531) | |||||||||
| Purchase of intangible assets | (15,226) | — | |||||||||
| Proceeds from short-term investments | — | 5,383 | |||||||||
| Purchase of businesses, net of cash acquired | (62,000) | (32,792) | |||||||||
| Net cash used in investing activities | (106,817) | (42,940) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Common stock repurchased | (40,370) | — | |||||||||
| Ordinary shares repurchased | — | (14,420) | |||||||||
| Proceeds from exercises of warrants | — | 23,509 | |||||||||
| Proceeds from exercises of options | 34,453 | — | |||||||||
| Principal payments on finance lease obligations | (875) | (740) | |||||||||
| Payment for credit facility financing fees | (2,179) | — | |||||||||
| Net cash (used in) provided by financing activities | (8,971) | 8,349 | |||||||||
| Effect of foreign currency on cash and cash equivalents | 5,110 | (2,617) | |||||||||
| Net change in cash and cash equivalents | 127,471 | 151,180 | |||||||||
| Cash and cash equivalents, beginning of period | 198,456 | 47,276 | |||||||||
| Cash and cash equivalents, end of period | $ | 325,927 | $ | 198,456 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Cash paid for interest | $ | 36,745 | $ | 37,317 | |||||||
| Cash paid for income taxes | $ | 48,851 | $ | 74,559 | |||||||
| Non-cash activities: | |||||||||||
| Liability portion of founders advisory fees - related party reclassified to additional paid in capital | $ | 138,823 | $ | 8,464 | |||||||
| (Unaudited) | Three Months Ended December 31, 2025 | Three Months Ended December 31, 2024 | |||||||||||||||||||||||||||||||||
| Fire Safety | Specialty Products | Total | Fire Safety | Specialty Products | Total | ||||||||||||||||||||||||||||||
| (Loss) income before income taxes | $ | (152,325) | $ | (22,103) | $ | (174,428) | $ | 45,304 | $ | 4,625 | $ | 49,929 | |||||||||||||||||||||||
| Depreciation and amortization | 14,579 | 5,843 | 20,422 | 12,858 | 3,645 | 16,503 | |||||||||||||||||||||||||||||
| Interest and financing expense (benefit) | 5,969 | 3,722 | 9,691 | 9,694 | (525) | 9,169 | |||||||||||||||||||||||||||||
| Founders advisory fees - related party | 154,106 | 17,103 | 171,209 | (46,936) | (7,853) | (54,789) | |||||||||||||||||||||||||||||
Non-recurring expenses (1) | 137 | 775 | 912 | 3,743 | 626 | 4,369 | |||||||||||||||||||||||||||||
| Acquisition costs | — | 2,716 | 2,716 | — | 612 | 612 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 3,390 | 1,829 | 5,219 | 2,735 | 2,066 | 4,801 | |||||||||||||||||||||||||||||
| Foreign currency (gain) loss | (323) | 534 | 211 | (154) | 2,434 | 2,280 | |||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 25,533 | $ | 10,419 | $ | 35,952 | $ | 27,244 | $ | 5,630 | $ | 32,874 | |||||||||||||||||||||||
| (1) | For the three months ended December 31, 2025, $0.7 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company and $0.2 million was related to the redomiciliation of the Company from Luxembourg to Delaware (the “Redomiciliation Transaction”). For the three months ended December 31, 2024, $4.4 million was related to the Redomiciliation Transaction and other non-recurring Luxembourg related costs. | |||||||||||||
| (Unaudited) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | |||||||||||||||||||||||||||||||||
| Fire Safety | Specialty Products | Total | Fire Safety | Specialty Products | Total | ||||||||||||||||||||||||||||||
| Loss before income taxes | $ | (182,537) | $ | (53,710) | $ | (236,247) | $ | (35,277) | $ | (11,586) | $ | (46,863) | |||||||||||||||||||||||
| Depreciation and amortization | 55,397 | 18,635 | 74,032 | 51,365 | 14,353 | 65,718 | |||||||||||||||||||||||||||||
| Interest and financing expense | 24,059 | 15,076 | 39,135 | 39,547 | 914 | 40,461 | |||||||||||||||||||||||||||||
| Founders advisory fees - related party | 381,106 | 54,057 | 435,163 | 169,886 | 28,422 | 198,308 | |||||||||||||||||||||||||||||
Non-recurring expenses (1) | 955 | 1,465 | 2,420 | 5,559 | 1,207 | 6,766 | |||||||||||||||||||||||||||||
| Acquisition costs | 98 | 3,480 | 3,578 | — | 612 | 612 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 12,207 | 4,440 | 16,647 | 8,545 | 4,304 | 12,849 | |||||||||||||||||||||||||||||
| Foreign currency (gain) loss | (798) | (2,240) | (3,038) | 496 | 1,947 | 2,443 | |||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 290,487 | $ | 41,203 | $ | 331,690 | $ | 240,121 | $ | 40,173 | $ | 280,294 | |||||||||||||||||||||||
| (1) | For the year ended December 31, 2025, $1.1 million was related to restructuring and other non-recurring costs, $0.7 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company, and $0.6 million was related to the Redomiciliation Transaction. For the year ended December 31, 2024, $6.6 million was related to the Redomiciliation Transaction and other non-recurring Luxembourg related costs and $0.2 million was related to other non-recurring costs. | |||||||||||||
| (Unaudited) | Three Months Ended December 31, | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| GAAP net (loss) income | $ | (140,231) | $ | 144,170 | |||||||||||||
| Adjustments: | |||||||||||||||||
| Amortization | 15,794 | 13,741 | |||||||||||||||
| Founders advisory fees - related party | 171,209 | (54,789) | |||||||||||||||
Non-recurring expenses (1) | 912 | 4,369 | |||||||||||||||
| Acquisition costs | 2,716 | 612 | |||||||||||||||
| Stock-based compensation expense | 5,219 | 4,801 | |||||||||||||||
| Foreign currency loss | 211 | 2,280 | |||||||||||||||
Tax impact of non-GAAP adjustments (2) | (35,937) | (96,136) | |||||||||||||||
| Adjusted net income | $ | 19,893 | $ | 19,048 | |||||||||||||
| Shares used in computing GAAP (Loss) Earnings Per Share (diluted) | 148,808,784 | 160,931,755 | |||||||||||||||
Options (3) | 7,136,522 | — | |||||||||||||||
Shares underlying Founders fixed advisory fees (4) | — | (9,428,244) | |||||||||||||||
Shares underlying Founders variable advisory fees (5) | — | — | |||||||||||||||
| Shares used in computing Adjusted Earnings Per Share (diluted) | 155,945,306 | 151,503,511 | |||||||||||||||
| GAAP (Loss) Earnings Per Share (diluted) | $ | (0.94) | $ | 0.90 | |||||||||||||
| Adjusted Earnings Per Share (diluted) | $ | 0.13 | $ | 0.13 | |||||||||||||
| ____________________ | |||||||||||||||||
| (1) | For the three months ended December 31, 2025, $0.7 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company and $0.2 million was related to the Redomiciliation Transaction. For the three months ended December 31, 2024, $4.4 million was related to the Redomiciliation Transaction and other non-recurring Luxembourg related costs. | ||||||||||||||||
| (2) | The tax impact of non-GAAP adjustments reflects the total income tax expense commensurate with the non-GAAP measure of profitability. | ||||||||||||||||
| (3) | The Company adds back the dilutive impact of options if amounts were excluded for purposes of GAAP EPS due to a GAAP net loss during the period. | ||||||||||||||||
| (4) | As of December 31, 2025, a maximum of 2.4 million shares were issuable within 12 months under the Founders fixed advisory fee. To satisfy the 2025 Founders fixed advisory fee, the Company paid $13.4 million in cash on February 19, 2026 and expects to issue 1.9 million shares of Common Stock in the first quarter of 2026. | ||||||||||||||||
| (5) | Based on period end market prices as of December 31, 2025, a maximum of 14.5 million shares were issuable within 12 months under the Founders variable advisory fee. To satisfy the 2025 Founders variable advisory fee, the Company paid $82.3 million in cash on February 19, 2026 and expects to issue 11.5 million shares of Common Stock in the first quarter of 2026. | ||||||||||||||||
| (Unaudited) | Year Ended December 31, | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| GAAP net loss | $ | (206,366) | $ | (5,905) | |||||||||||||
| Adjustments: | |||||||||||||||||
| Amortization | 59,696 | 55,032 | |||||||||||||||
| Founders advisory fees - related party | 435,163 | 198,308 | |||||||||||||||
Non-recurring expenses (1) | 2,420 | 6,766 | |||||||||||||||
| Acquisition costs | 3,578 | 612 | |||||||||||||||
| Stock-based compensation expense | 16,647 | 12,849 | |||||||||||||||
| Foreign currency (gain) loss | (3,038) | 2,443 | |||||||||||||||
Tax impact of non-GAAP adjustments (2) | (101,427) | (106,715) | |||||||||||||||
| Adjusted net income | $ | 206,673 | $ | 163,390 | |||||||||||||
| Shares used in computing GAAP (Loss) Earnings Per Share (diluted) | 150,370,533 | 145,713,439 | |||||||||||||||
Options (3) | 4,092,617 | 1,446,487 | |||||||||||||||
Warrants (3) | — | 49,876 | |||||||||||||||
Shares underlying Founders fixed advisory fees (4) | — | — | |||||||||||||||
Shares underlying Founders variable advisory fees (5) | — | — | |||||||||||||||
| Shares used in computing Adjusted Earnings Per Share (diluted) | 154,463,150 | 147,209,802 | |||||||||||||||
| GAAP (Loss) Earnings Per Share (diluted) | $ | (1.37) | $ | (0.04) | |||||||||||||
| Adjusted Earnings Per Share (diluted) | $ | 1.34 | $ | 1.11 | |||||||||||||
| ____________________ | |||||||||||||||||
| (1) | For the year ended December 31, 2025, $1.1 million was related to restructuring and other non-recurring costs, $0.7 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company, and $0.6 million was related to the Redomiciliation Transaction. For the year ended December 31, 2024, $6.6 million was related to the Redomiciliation Transaction and other non-recurring Luxembourg related costs and $0.2 million was related to other non-recurring costs. | ||||||||||||||||
| (2) | The tax impact of non-GAAP adjustments reflects the total income tax expense commensurate with the non-GAAP measure of profitability. | ||||||||||||||||
| (3) | The Company adds back the dilutive impact of options and warrants if amounts were excluded for purposes of GAAP EPS due to GAAP net loss during the period. | ||||||||||||||||
| (4) | As of December 31, 2025, a maximum of 2.4 million shares were issuable within 12 months under the Founders fixed advisory fee. To satisfy the 2025 Founders fixed advisory fee, the Company paid $13.4 million in cash on February 19, 2026 and expects to issue 1.9 million shares of Common Stock in the first quarter of 2026. | ||||||||||||||||
| (5) | Based on period end market prices as of December 31, 2025, a maximum of 14.5 million shares were issuable within 12 months under the Founders variable advisory fee. To satisfy the 2025 Founders variable advisory fee, the Company paid $82.3 million in cash on February 19, 2026 and expects to issue 11.5 million shares of Common Stock in the first quarter of 2026. | ||||||||||||||||